Tokyo, Japan
Tokyo, Japan

Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 1,148.2 billion in revenue in 2013. The company owns the American biotechnology company Plexxikon, the German biotechnology company U3 Pharma and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar , an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo, Company, Limited and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development , is headquartered in Parsippany, New Jersey.Daiichi Sankyo Europe, GmbH , the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries. Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations . In 2009, the highly respected magazine R&D Direction honoured Daiichi Sankyo with its "Best Cardiovascular Pipeline Award". Wikipedia.


Time filter

Source Type

An object of the present invention is to provide a high-purity crystal of a compound represented by formula (1a) that is an activated blood coagulation factor X (FXa) inhibitor. Solution: High-purity crystals of a compound represented by the following formula (1a):


Patent
Daiichi Sankyo | Date: 2017-01-09

The present invention provides methods for manufacturing neuraminic acid derivatives. [Means for solution] Methods for manufacturing compounds represented by the formula (I): [wherein R^(1 )represents a C_(1)-C_(19 )alkyl group], or a pharmacologically acceptable salt thereof, using N-acetylneuraminic acid dihydrate as a starting raw material are provided.


Patent
Daiichi Sankyo | Date: 2017-05-17

It is intended to provide a novel compound or a salt thereof, or crystals of the compound or the salt, which inhibit Axl and are useful in the treatment of a disease caused by hyperfunction of Axl, the treatment of a disease associated with hyperfunction of Axl, and/or the treatment of a disease involving hyperfunction of Axl. [Solution] The present invention provides a pyridone derivative having a tetrahydropyranylmethyl group represented by the following formula (I) having various substituents, or a salt thereof, or crystals of the compound or the salt (wherein R_(1), R_(2), R_(3), R_(4), R_(5), W, X, Y, and Z are each as defined in the specification).


An object of the present invention is to provide a pharmaceutical composition having abuse deterrent properties and thereby prevent the abuse of a pharmacologically active component by an abuser (abuse through snorting, abuse through injection, or abuse through snorting or injection of a temporarily extracted drug). The present invention provides a pharmaceutical composition having abuse deterrent properties that possesses both a physical barrier and a chemical barrier to being abused by an abuser, a method for producing the same and a method for using the same.


Patent
Daiichi Sankyo | Date: 2017-06-14

It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.


Patent
Daiichi Sankyo | Date: 2017-02-28

The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.


Patent
Daiichi Sankyo | Date: 2017-06-21

The present invention relates to novel antibodies against the FGF receptor 4 (FGFR4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with FGFR expression, over expression or hyperactivity.


The invention provides methods of treating or preventing bleeding events or over- anticoagulation in a subject in need thereof who is identified as having sensitivity to a vitamin K antagonist such as warfarin by administering to the subject a therapeutically effective amount of an FXa inhibitor, which can be a direct or indirect FXa inhibitor, or a warfarin or VKA alternative drug or compound. The direct FXa inhibitor can be the small molecule edoxaban p- toluenesulfonate monohydrate, edoxaban, or a pharmaceutically acceptable salt and/or hydrate thereof. In aspects, the subject is identified as having one or more genetic polymorphisms in genes CYP2C9 and/or VKORC1 resulting in loss of function, reduction in function, or aberrant function of these genes and/or their protein products, and sensitivity to warfarin. The invention provides methods of administering an FXa inhibitor or warfarin alternative to safely and effectively reduce, prevent, reduce the risk of, prevent the recurrence of, or prevent the risk of recurrence of, conditions such as embolism, thrombosis, thromboembolism, etc. in a subject who is in need of anticoagulant therapy and who is identified as having one or more genetic polymorphisms resulting in warfarin sensitivity.


The present invention relates to the treatment of osteogenesis imperfecta with anti-Siglec-15 antibodies or antigen binding fragment thereof. Treatment of osteogenesis imperfecta type VI is particularly contemplated.


Patent
Daiichi Sankyo and U3 Pharma GmbH | Date: 2017-02-15

To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH-(CH2)n1-La-(CH2)n2-C(=O)- or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of -(CH2)n2-C(=O)- moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).

Loading Daiichi Sankyo collaborators
Loading Daiichi Sankyo collaborators